NASDAQ
123.96USD
0.00 (0.00%)
We have scored 12 news catalysts on Nuvalent, Inc. (NUVL) over the past 12 months. The biggest single-day move next to one of them came Nov 19, 2025, when NUVL closed +2.8%: “Biotech Stock Gets Booted in Latest Fund Update”. Coverage across the window leans mixed (average ticker sentiment −0.06). Most of the impact sits in institutional appeal and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
9.1B
P/E
—
EPS
—
Beta
1.14
52W range
71.13-123.99
Day range
123.96–123.96
Open
123.96
Prev close
123.96
Volume
0
Avg volume
2.3M
Dividend
0.00
IPO
2021-07-29
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Nuvalent, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for NUVL: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
